The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Intention‐to‐treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases
Abstract
Since it came up in the 1960s, the principle of intention‐to‐treat (ITT) has become widely accepted for the analysis of controlled clinical trials. In this context the question of how to perform such an analysis in the presence of missing information about the main endpoint is of major importance. Uncritical use of several ad hoc strategies for dealing with missing values is common in the practice of clinical trials. On the other hand, little is known about possible dangers and problems of applying these strategies. We therefore performed a detailed investigation of different methods for dealing with missing values in order to develop recommendations for their practical use. A simulation study was performed investigating possible consequences on type I error and power of applying different methods for dealing with missing values. The simulations were based on a clinical trial of osteoporosis, a progressively deteriorating disease. The strategies examined can be roughly classified into numerical imputation strategies (last observation carried forward, mean and regression based methods) and non‐parametric strategies (rank and dichotomization based methods). Different drop‐out mechanisms and different types of progression of disease are considered. The type I error increases drastically for the different strategies, especially if the courses of disease vary between treatment groups. The loss in power can be substantial. There is no strategy which is adequate for all different combinations of drop‐out mechanisms, drop‐out rates and courses of disease over time. For drop‐out rates less than 20 per cent and similar courses of disease in the treatment groups, missing values might be replaced by the mean of the other group, or counted as treatment failures after dichotomization of the endpoint. For larger drop‐out rates or less similar courses of disease, no adequate recommendations can be given. Because of the drastic consequences of increasing drop‐out rates, it has to be a primary goal in clinical trials to keep missing values to a minimum. Unobserved information cannot be reliably regained by any methodological resources. As there are no strategies for universal use, reasons for the choice of a certain method have to be provided when designing and analysing clinical trials. Copyright © 2001 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Statistical Analysis with Missing Data.
Chatfield, C., Little, R. J. A., & Rubin, D. B. (1988) · Journal of the Royal Statistical Society. Series A (Statistics in Society) · doi:10.2307/2982783 · Cited by 2,202
Modeling the Drop-Out Mechanism in Repeated-Measures Studies
Little, R. J. A. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476615 · Cited by 1,522
Missing data in longitudinal studies
Laird, N. M. (1988) · Statistics in Medicine · doi:10.1002/sim.4780070131 · Cited by 713
Statistical Issues in Drug Development
Senn, S. (2007) · doi:10.1002/9780470723586 · Cited by 448
Statistical Issues in Drug Development
Senn, S. (2021) · Wiley eBooks · doi:10.1002/9781119238614 · Cited by 384
Fundamentals of Clinical Trials
Rhoads, G. G. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380080101043 · Cited by 342
Second-Order Analysis of Spatial Clustering for Inhomogeneous Populations
Diggle, P. J., & Chetwynd, A. G. (1991) · Biometrics · doi:10.2307/2532668 · Cited by 336
Surrogate endpoints in clinical trials: Cardiovascular diseases
Wittes, J., Lakatos, E., & Probstfield, J. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080405 · Cited by 247
Minne, H. W., Leidig, G., Wüster, C. C., Siromachkostov, L., Baldauf, G., Bickel, R., Sauer, P., Lojen, M., & Ziegler, R. C. (1988) · PubMed · Cited by 233
The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials
Gillings, D., & Koch, G. (1991) · Drug Information Journal · doi:10.1177/009286159102500311 · Cited by 228
The randomized clinical trial: bias in analysis.
May, G. S., DeMets, D. L., Friedman, L. M., Furberg, C. D., & Passamani, E. R. (1981) · Circulation · doi:10.1161/01.cir.64.4.669 · Cited by 152
Principles of medical statistics
(1961) · Public Health · doi:10.1016/s0033-3506(61)80172-8 · Cited by 115
A New Approach to the Analysis of Clinical Drug Trials with Withdrawals
Gould, A. L. (1980) · Biometrics · doi:10.2307/2556126 · Cited by 113
Minne, H., Leidig, G., & Wüster, C. C. (1988) · Maturitas · doi:10.1016/0378-5122(88)90041-2 · Cited by 78
General design issues in efficacy, equivalency and superiority trials
Fleiss, J. L. (1992) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.1992.tb01684.x · Cited by 49
Sensitivity Analysis by Worst and Best Case Assessment: Is it Really Sensitive?
Unnebrink, K., & Windeler, J. (1999) · Drug Information Journal · doi:10.1177/009286159903300324 · Cited by 24
Self-citation
Cited by
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
(2008) · Cited by 3,790
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Avery, K. N. L., Williamson, P. R., Gamble, C., O'Connell Francischetto, E., Metcalfe, C., Davidson, P., Williams, H., & Blazeby, J. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013537 · Cited by 575
Wood, A. M., White, I. R., & Thompson, S. G. (2004) · Clinical Trials · doi:10.1191/1740774504cn032oa · Cited by 543
Metadata
- Authors
- Unnebrink, K., & Windeler, J.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2001-12-20
- Volume
- 20
- Issue
- 24
- Pages
- 3931-3946
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W1993228662
- Cited by
- 258
- References
- 18
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.